EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

Andrew B Lassman iD, Stephanie L Pugh, Tony J C Wang, Kenneth Aldape iD, Hui K Gan, Matthias Preusser iD, Michael A Vogelbaum, Erik P Sulman, Minhee Won, Peixin Zhang, Golnaz Moazami, Marian S Macsai und 20 weitere

Neuro-Oncology · 14.02.2023 · 25 (2) · 339-350

DOI: 10.1093/neuonc/noac173 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Neuro-Oncology, online erschienen am 15.07.2022. Verfasst von Andrew B Lassman und 31 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian Hospita…. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 173-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Cancer Institute, National Institutes of Health, ABB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor epidermal growth factor receptor gene amplification (EGFR-amp). Preclinical and early-phase clinical data suggested efficacy of depatuxizumab mafodotin (depatux-m), an antibody–drug conjugate comprised of a monoclonal antibody that binds activated EGFR (overexpressed wild-type and EGFRvIII-mutant) linked to a microtubule-inhibitor toxin in EGFR-amp GBMs.

Methods

In this phase III trial, adults with centrally confirmed, EGFR-amp newly diagnosed GBM were randomized 1:1 to radiotherapy, temozolomide, and depatux-m/placebo. Corneal epitheliopathy was treated with a combination of protocol-specified prophylactic and supportive measures. There was 85% power to detect a hazard ratio (HR) ≤0.75 for overall survival (OS) at a 2.5% 1-sided significance level (ie traditional two-sided p ≤ 0.05) by log-rank testing.

Results

There were 639 randomized patients (median age 60, range 22–84; 62% men). Prespecified interim analysis found no improvement in OS for depatux-m over placebo (median 18.9 vs. 18.7 months, HR 1.02, 95% CI 0.82–1.26, 1-sided p = 0.63). Progression-free survival was longer for depatux-m than placebo (median 8.0 vs. 6.3 months; HR 0.84, 95% confidence interval [CI] 0.70–1.01, p = 0.029), particularly among those with EGFRvIII-mutant (median 8.3 vs. 5.9 months, HR 0.72, 95% CI 0.56–0.93, 1-sided p = 0.002) or MGMT unmethylated (HR 0.77, 95% CI 0.61–0.97; 1-sided p = 0.012) tumors but without an OS improvement. Corneal epitheliopathy occurred in 94% of depatux-m-treated patients (61% grade 3–4), causing 12% to discontinue.

Conclusions

Interim analysis demonstrated no OS benefit for depatux-m in treating EGFR-amp newly diagnosed GBM. No new important safety risks were identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsAdultMaleHumansMiddle AgedFemaleAntibodies, Monoclonal, HumanizedTemozolomideErbB Receptors

Stichwörter der Autor:innen

EGFRantibody drug conjugatedepatuxizumab mafodotinglioblastomaphase III

Substanzen

depatuxizumab mafodotinAntibodies, Monoclonal, HumanizedTemozolomideErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian Hospital, New York, New York, USA.
  • Herbert Irving Comprehensive Cancer Center, New York, New York, USA.
  • RTOG Foundation Statistics and Data Management Center, American College of Radiology, Philadelphia, Pennsylvania.
  • Department of Radiation Oncology (in Neurological Surgery), Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian Hospital, New York, New York, USA.
  • Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
  • Cancer Therapies and Biology Group, Centre of Research Excellence in Brain Tumours, Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Melbourne, Australia.

ORCID-Profile: Andrew B Lassman, Kenneth Aldape, Matthias Preusser, Madan G Kundu, Giuseppe Lombardi

Förderung

  • National Cancer Institute
  • National Institutes of Health
  • ABB
  • AbbVie
  • Clough

Zitieren

APA

Lassman, A. B., Pugh, S. L., Wang, T. J. C., Aldape, K., Gan, H. K., Preusser, M., Vogelbaum, M. A., Sulman, E. P., Won, M., Zhang, P., Moazami, G., Macsai, M. S., Gilbert, M. R., Bain, E. E., Blot, V., Ansell, P. J., Samanta, S., Kundu, M. G., Armstrong, T. S., …, & Mehta, M. P. (2023). Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro-Oncology, 25(2), 339-350. https://doi.org/10.1093/neuonc/noac173

Vancouver

Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro-Oncology. 2023;25(2):339-350. doi:10.1093/neuonc/noac173

BibTeX
@article{Lassman2023,
  author = {Lassman, Andrew B and Pugh, Stephanie L and Wang, Tony J C and Aldape, Kenneth and Gan, Hui K and Preusser, Matthias and Vogelbaum, Michael A and Sulman, Erik P and Won, Minhee and Zhang, Peixin and Moazami, Golnaz and Macsai, Marian S and Gilbert, Mark R and Bain, Earle E and Blot, Vincent and Ansell, Peter J and Samanta, Suvajit and Kundu, Madan G and Armstrong, Terri S and Wefel, Jeffrey S and Seidel, Clemens and de Vos, Filip Y and Hsu, Sigmund and Cardona, Andrés F and Lombardi, Giuseppe and Bentsion, Dmitry and Peterson, Richard A and Gedye, Craig and Bourg, Véronique and Wick, Antje and Curran, Walter J and Mehta, Minesh P},
  title = {Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial},
  journal = {Neuro-Oncology},
  year = {2023},
  volume = {25},
  number = {2},
  pages = {339--350},
  doi = {10.1093/neuonc/noac173}
}
Kostenlos starten →